肥胖症新药瑞他鲁肽显示显著减重效果

肥胖症治疗领域出现重大进展。研究人员发布的三期临床试验数据显示，新药瑞他鲁肽在控制体重方面效果显著，其中最高剂量组患者在80周内平均减重25%，到104周时这一比例上升至30%1。试验中超过三分之一的参与者减重幅度超过30%1。

该试验涉及来自11个国家131个临床试验点的2,339名参与者1，参与者被分为四组，分别接受4毫克、9毫克、12毫克瑞他鲁肽或安慰剂治疗1。除了减重效果外，瑞他鲁肽还在缓解肥胖相关并发症方面表现突出：膝关节骨关节炎疼痛减少高达62%1，睡眠呼吸暂停事件减少高达57%1，前驱糖尿病患者中超过90%的病情得到缓解1。这些结果已发表在《新英格兰医学杂志》上1。

Researchers have released Phase 3 clinical trial data for retatrutide, a new obesity treatment demonstrating significant efficacy in weight reduction and related health improvements. 1 Participants receiving the highest dose achieved an average weight loss of 25% over 80 weeks, with results reaching 30% by the 104-week mark. 1 More than one-third of trial participants lost more than 30% of their body weight. 1

The trial involved 2,339 participants across 131 clinical sites in 11 countries, divided into four treatment groups receiving doses of 4 milligrams, 9 milligrams, 12 milligrams, or placebo. 1 Beyond weight reduction, retatrutide demonstrated substantial improvements in obesity-related complications: knee osteoarthritis pain decreased by up to 62%, sleep apnea events declined by as much as 57%, and over 90% of participants with prediabetes experienced disease remission. 1 The findings have been published in the New England Journal of Medicine. 1